Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis

Chen, Fan; Zhou, Jing; Luo, Fang; Mohammed, Al-Bayati; Zhang, Xiaolian

doi:10.1016/j.bbrc.2007.04.007

Cited by 196 publications

(135 citation statements)

References 21 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Aptamers can target against some of the surface proteins of microorganism, and the growth of the bacteria can be inhibited. The only example of therapeutic aptamer with antimicrobial properties has been demonstrated with virulent Mycobacterium tuberculosis (Chen et al, 2007).…”

Section: Aptamers Targeting Microbial Cellsmentioning

confidence: 99%

Aptamer-Nanoparticle Bioconjugates for Drug Delivery

Özalp¹,

Schäfer²

2012

The Delivery of Nanoparticles

View full text Add to dashboard Cite

Section: Aptamers Targeting Microbial Cellsmentioning

confidence: 99%

Aptamer-Nanoparticle Bioconjugates for Drug Delivery

Özalp¹,

Schäfer²

2012

The Delivery of Nanoparticles

View full text Add to dashboard Cite

“…Since the discovery of SELEX technology in 1990, aptamers have received tremendous attention in the fields of targeted drug delivery (Chu et al, 2006b;Chu et al, 2006a;Farokhzad et al, 2006;Huang et al, 2009;McNamara et al, 2006), diagnosis Tang et al, 2007), imaging (Blank et al, 2001;Schäfer et al, 2007), target validation (Blank and Blind, 2005;Cerchia and de Franciscis, 2007), therapeutics (Bock et al, 1992;Cosmi, 2009), biosensing (Bing et al, 2010;Liu et al, 2009), and cell fishing (Guo et al, 2006;Schäfer et al, 2007;Pan et al, 2010). After 20 years of effort, aptamers have been generated against a broad range of targets, including small molecules, peptides, proteins, drugs, and even whole cells (Daniels et al, 2003;Cerchia et al, 2005;Ohuchi et al, 2006;Mallikaratchy et al, 2007;Raddatz et al, 2008) or organisms (Ulrich et al, 2002;Chen et al, 2007).…”

Section: Aptamersmentioning

confidence: 99%

Current concepts and new developments for autologous in vivo endothelialisation of biomaterials for intravascular applications

Avci‐Adali

Perle²,

Ziemer³

et al. 2011

eCM

View full text Add to dashboard Cite

Circulating endothelial progenitor cells (EPCs) in the peripheral blood of adults represent an auspicious cell source for tissue engineering of an autologous endothelium on blood-contacting implants. Novel materials biofunctionalised with EPC-specific capture molecules represent an intriguing strategy for induction of selective homing of progenitor cells. The trapped EPCs can differentiate into endothelial cells and generate a nonthrombogenic surface on artificial materials. However, the success of this process mainly depends on the use of optimised capture molecules with a high selectivity and affinity. In recent years, various biomedical engineering strategies have emerged for in situ immobilisation of patient's own stem cells on blood contacting materials. The realisation of this in vivo tissue engineering concept and generation of an endothelium on artificial surfaces could exceedingly enhance the performance of not only small calibre vascular grafts and stents, but also, in general all blood-contacting medical devices, such as heart valves, artificial lungs, hearts, kidneys, and ventricular assist devices.

show abstract

“…In addition to identification of cancer cells in heterogeneous cell mixture (17), the recognition of cell surface epitopes that are either specifically or differentially expressed in diseased cells relative to healthy cells has been exploited to distinguish vaccinia-virus cells infected from uninfected cells (18). Aptamers binding to Mycobacterium tuberculosis (19), kinetoplastid membrane protein-11 (KMP-11) of Leishmania infantum (20), or to specific cell surface antigens of T. cruzi (21) or T. brucei (22) may be used for diagnosis of bacterial or parasite infection. Like antibodies, aptamers can be easily tagged with fluorescence reporters or nanoparticles for localization-or pull-down-experiments of target proteins (7).…”

Section: The Selex Technologymentioning

confidence: 99%

Disease‐specific biomarker discovery by aptamers

Ulrich

Wrenger

2009

Cytometry Pt A

View full text Add to dashboard Cite

RNA and DNA aptamers developed by an in vitro selection process, Systematic Evolution of Ligands by EXponential enrichment (SELEX), comprise a novel class of highaffinity and specific capture agents, which can be easily modified for cytometry and in vivo applications. A novel application of this technique (Cell SELEX) explores the expression of cell surface epitopes that differ between two given cell types or between healthy and diseased cells. Using whole cells as targets, aptamer libraries can be identified that bind to biomarkers expressed by target cells and not by any other cells. Aptamers have been developed that specifically interact with cell surface epitopes of trypanosomes or distinguish between the differences in molecular signature of somatic and cancer cells. Aside from its use for target cell identification by image and flow cytometry and laser-scanning microscopy, aptamers can be used for ligand-mediated purification and identification of their binding proteins in target cell membranes. In this review, we discuss an approach for the development of aptamers targeting parasitederived surface proteins of Trypanosoma and Plasmodium. ' 2009 International Society for Advancement of CytometryKey terms aptamers; Plasmodium falciparum; deconvolution SELEX; cell and target protein identification; fluorescence-labeled aptamers for clinical and cytomics application THE SELEX TECHNOLOGYThe SELEX technique (Systematic Evolution of Ligands by EXponential enrichment) initially developed by the laboratories of Larry Gold (1) and Jack Szostak (2) uses iterative in vitro selection of combinatorial RNA or DNA pools against a target molecule for the identification of high-affinity oligonucleotide ligands, known as aptamers. This methodology has been extensively used to isolate aptamers for a wide variety of peptides and proteins of therapeutic importance, including growth and coagulation factors (3). This novel class of oligonucleotide-based ligands recognizes their targets with binding specificities and affinities comparable to those of monoclonal antibodies. Moreover, aptamers are able to distinguish between protein isoforms and different conformational forms of the same protein (4,5). In most cases, aptamer binding to its target protein inhibits its biological activity, either resulting from aptamer interference with the catalytic site of an enzyme or with sites involved in ligandreceptor recognition. However, it is also possible that aptamer-target protein binding induces allosteric effects, such as changes in conformational states resulting in loss of biological activity of the target protein.Aptamers can be identified by in vitro selection against almost any target, including toxins and antigens which do not induce immune responses in host animals for antibody production. As a result, this novel class of ligands is highly promising for the development of therapeutics and biotechnological tools. The potential utility of aptamers for in vivo applications and as therapeutic agents is considerably enhanced ...

show abstract

Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis

Cited by 196 publications

References 21 publications

Aptamer-Nanoparticle Bioconjugates for Drug Delivery

Aptamer-Nanoparticle Bioconjugates for Drug Delivery

Current concepts and new developments for autologous in vivo endothelialisation of biomaterials for intravascular applications

Disease‐specific biomarker discovery by aptamers

Contact Info

Product

Resources

About